0QYQ.LSE Gilead Sciences Inc.

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
0.05%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0QYQ.LSE undervalued?

Graham number

The Graham number of Gilead Sciences Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gilead Sciences Inc. fundamental analysis

No fundamental analysis for Gilead Sciences Inc. yet.

Gilead Sciences Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus,…

Full company profile